白蛋白结合型紫杉醇治疗晚期恶性肿瘤的疗效

Efficacy of albumin-bound paclitaxel in the treatment of advanced malignant tumors

目的观察白蛋白结合型紫杉醇治疗晚期恶性肿瘤的近期疗效和毒副作用。方法 26例晚期恶性肿瘤患者接受含白蛋白结合型紫杉醇125mg/m2方案化疗,第1、8、15天用药,每28天为1周期,共2～4个周期。结果 26例患者中完全缓解(CR)1例(3.85%),部分缓解(PR)11例(42.31%),疾病稳定(SD)3例(11.54%),疾病进展(PD)11例(42.31%),有效率(RR)为46.15%(12/26),疾病控制率(DCR)为57.69%(15/26)。不良反应主要为Ⅲ～Ⅳ度中性粒细胞减少,发生率为61.54%(16/26)。结论白蛋白结合型紫杉醇每周方案治疗晚期恶性肿瘤疗效较好,不良反应可以耐受。

Objective To evaluate the efficacy of albumin-bound paclitaxel in the treatment of patients with advanced malignant tumors.Methods Twenty-six patients with malignant tumors were treated by 2-4 cycles of chemotherapy with albumin-bound paclitaxel and other chemotherapy drugs.Albumin-bound paclitaxel 125 mg/m2 was administered on days 1,8 and 15 of a 28-day cycle.ResultsAmong 26 patients,one case（3.85%） and eleven（42.31%） patients had complete or partial response,respectively,with an overall response rate of 46.15%.The diseases in three cases（11.54%） remained stable and in eleven（42.31%） progressed.The disease control rate was 57.69%（15/26）.Neutropenia was the commonest toxicity and the incidence rate of grades 3 and 4 neutropenia was 61.54%.Conclusion The albumin-bound paclitaxel has good effectiveness in treating advanced malignant tumors with well tolerated side effects.